Literature DB >> 8789393

Increase in insulin release from rat pancreatic islets by quinolone antibiotics.

N Maeda1, T Tamagawa, I Niki, H Miura, K Ozawa, G Watanabe, K Nonogaki, K Uemura, A Iguchi.   

Abstract

1. The present study was undertaken to elucidate the mechanism(s) of hypoglycaemia caused by quinolone antibiotics. We investigated the effects of various quinolone antibiotics on insulin release in rat pancreatic islets. 2. At a non-stimulatory concentration of 3 mM glucose, lomefloxacin (LFLX) or sparfloxacin at 1 mM and pipemidic acid (0.1-1 mM) induced slight insulin release but tosufloxacin or enoxacin up to 100 microM did not. 3. At the stimulatory concentration of 10 mM glucose, all quinolones augmented insulin release in a dose-dependent manner. LFLX (100 microM) shifted the dose-response curve of glucose-induced insulin release to the left without altering the maximal response. 4. At 10 mM glucose, LFLX (100 microM) increased insulin release augmented by forskolin (5 microM) or 12-O-tetradecanoyl phorbol-13-acetate (100 nM) but not by raising the K+ concentration from 6 to 25 mM. 5. Verapamil (50 microM) or diazoxide (50-400 microM) antagonized the insulinotropic effect of LFLX. 6. These data suggest that quinolone antibiotics may cause hypoglycaemia by increasing insulin release via blockade of ATP-sensitive K+ channels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789393      PMCID: PMC1909264          DOI: 10.1111/j.1476-5381.1996.tb15201.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Glucose-induced decrease in Rb+ permeability in pancreatic beta cells.

Authors:  J Sehlin; I B Taljedal
Journal:  Nature       Date:  1975-02-20       Impact factor: 49.962

2.  Effect of D-glucose on the incorporation of 32P into phospholipids of mouse pancreatic islets.

Authors:  G Fex; A Lernmark
Journal:  FEBS Lett       Date:  1972-09-15       Impact factor: 4.124

3.  Islet-activating protein. Enhanced insulin secretion and cyclic AMP accumulation in pancreatic islets due to activation of native calcium ionophores.

Authors:  T Katada; M Ui
Journal:  J Biol Chem       Date:  1979-01-25       Impact factor: 5.157

4.  The stimulus-secretion coupling of glucose-induced insulin release. 3. Uptake of 45 calcium by isolated islets of Langerhans.

Authors:  F Malaisse-Lagae; W J Malaisse
Journal:  Endocrinology       Date:  1971-01       Impact factor: 4.736

5.  Diazoxide and D600 inhibition of insulin release. Distinct mechanisms explain the specificity for different stimuli.

Authors:  J C Henquin; S Charles; M Nenquin; F Mathot; T Tamagawa
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

6.  Calcium-activated, phospholipid-dependent protein kinase in rat pancreas islets of langerhans. Its possible role in glucose-induced insulin release.

Authors:  K Tanigawa; H Kuzuya; H Imura; H Taniguchi; S Baba; Y Takai; Y Nishizuka
Journal:  FEBS Lett       Date:  1982-02-22       Impact factor: 4.124

7.  Opposite effects of tolbutamide and diazoxide on 86Rb+ fluxes and membrane potential in pancreatic B cells.

Authors:  J C Henquin; H P Meissner
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

8.  Effects of a phorbol ester and clomiphene on protein phosphorylation and insulin secretion in rat pancreatic islets.

Authors:  S J Hughes; S J Ashcroft
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

9.  Cyclic nucleotide phosphodiesterase of rat pancreatic islets. Effects of Ca2+, calmodulin and trifluoperazine.

Authors:  M C Sugden; S J Ashcroft
Journal:  Biochem J       Date:  1981-08-01       Impact factor: 3.857

10.  Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells.

Authors:  G Trube; P Rorsman; T Ohno-Shosaku
Journal:  Pflugers Arch       Date:  1986-11       Impact factor: 3.657

View more
  11 in total

1.  Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.

Authors:  Trisha M Parekh; Mukaila Raji; Yu-Li Lin; Alai Tan; Yong-Fang Kuo; James S Goodwin
Journal:  JAMA Intern Med       Date:  2014-10       Impact factor: 21.873

Review 2.  Clinically and pharmacologically relevant interactions of antidiabetic drugs.

Authors:  Marcus May; Christoph Schindler
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-31       Impact factor: 3.565

Review 3.  Dysglycaemias and fluoroquinolones.

Authors:  Roshan J Lewis; John F Mohr
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 4.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Recurrent episodes of hypoglycemia induced by moxifloxacin.

Authors:  Dinesh Kumar Singal; Amit Mittal; Anukalp Prakash
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 1.200

6.  Hypoglycemia revisited in the acute care setting.

Authors:  Shih-Hung Tsai; Yen-Yue Lin; Chin-Wang Hsu; Chien-Sheng Cheng; Der-Ming Chu
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

7.  Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia.

Authors:  Wissam K Kabbara; Wijdan H Ramadan; Peggy Rahbany; Souhaila Al-Natour
Journal:  Ther Clin Risk Manag       Date:  2015-04-22       Impact factor: 2.423

8.  Ciprofloxacin and risk of hypolycemia in non-diabetic patients.

Authors:  Abiel Berhe; Mulugeta Russom; Fithawit Bahran; Goitom Hagos
Journal:  J Med Case Rep       Date:  2019-05-12

9.  Fatal hypoglycemia with ciprofloxacin in a dialysis patient: A case report.

Authors:  Aisa Matoi; Mana Taguchi; Shinichi Nishi
Journal:  Clin Case Rep       Date:  2021-03-12

Review 10.  An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?

Authors:  Robert C Owens
Journal:  Crit Care       Date:  2008-05-21       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.